Loading...
Laboratorios Farmaceuticos Rovi Community
BME:ROVI Community- 2 Narratives written by author
- 0 Comments on narratives written by author
- 50 Fair Values set on narratives written by author
Community Investing Ideas
The future of Rovi is very uncertain, we must wait until the year 2026 to have a clear projection.
Recent Financial Performance In H1 2025, Rovi’s net profit dropped by 10% to €39.7 million. The decline was mainly due to reduced third-party manufacturing, especially COVID-19 vaccine production.Read more
1users have liked this narrative
0users have commented on this narrative
5users have followed this narrative
KA
€51.25
14.8% overvalued intrinsic discount
kapirey Fair Value
Revenue growth
4% p.a.
Profit Margin
18%
Future PE
24x
Share price in 2030
€78.86
Expanded CDMO And EU Investments Will Unlock Future Injectables Markets
Key Takeaways Strong growth in specialty pharmaceuticals and expanded manufacturing capacity position Rovi to benefit from global demand for innovative treatments and enhanced contract manufacturing. Advancements in proprietary drug development and vertical integration in heparin sourcing support diversified revenue streams and improved profitability amid rising industry competition.Read more
1users have liked this narrative
0users have commented on this narrative
23users have followed this narrative
AN
€79.41
25.9% undervalued intrinsic discount
AnalystConsensusTarget Fair Value
Revenue growth
9.14% p.a.
Profit Margin
24.45%
Future PE
21.12x
Share price in 2028
€98.33